Feb 24, 2026

Email 1:

Subject: How lobbyist strategies are changing under Trump’s FDA

Good morning,

Discover how the approach of drugmaker lobbyists to the FDA is shifting under the Trump administration. Traditionally, FDA decisions about drugs were shielded from political influence. However, now, the strategy focuses on “currying favor” with top officials amid an agency upheaval marked by dismissed experts and controversy. Learn how pharmaceutical companies are capitalizing on this new landscape.

Plus, the American College of Obstetricians and Gynecologists has released its first guidance for diagnosing endometriosis: treatment can begin based on symptoms or physical exams without immediately requiring laparoscopy. This shift could impact how clinicians approach this painful condition.

Also covered:

– Women’s cardiovascular risk profiles and new research insights.

– Bold predictions about AI replacing many doctors.

– Higher mental health disorder rates among adults with intellectual and developmental disabilities.

Stay informed on these critical health policy and research updates.

Best,

Theresa Gaffney, Morning Rounds Writer and Reporter

Email 2:

Subject: ⚕️ New 340B overhauls – What you need to know

Hello Vitals gang,

The Trump administration is pressing forward with changes to the federal 340B drug discount program, a central battleground between Big Pharma and healthcare providers. The new proposal would shift discounts from upfront price cuts to rebate systems, potentially disrupting hospitals’ cash flow and increasing administrative burdens. HHS is currently gathering financial data to assess these impacts.

Additionally, although a Supreme Court ruling struck down several tariff policies, tariff threats on drug imports remain. President Trump retains authority to impose certain tariffs to protect domestic pharmaceutical production, complicating ongoing drug price negotiations and investment.

Also in our briefing:

– Gene therapies’ growing cost impact on employer health plans.

– Insights on healthcare policy and political appointee actions affecting vaccine funding.

Stay current on these pivotal healthcare developments.

Best,

Maya Goldman, Peter Sullivan and Tina Reed, Axios Vitals Team

Email 3:

Subject: New Event: Join STAT@AACR live in San Diego — April 21st

Dear Colleague,

Join STAT at the American Association for Cancer Research (AACR) meeting in San Diego on April 21 for STAT@AACR: Outsmarting Cancer. This exclusive event highlights cutting-edge cancer research, including advances in targeted therapies, diagnosis, and monitoring.

This gathering offers a unique opportunity to engage with peers and experts in oncology and is open and free to all attending AACR. Reserve your spot today and stay connected with the latest scientific breakthroughs in cancer care.

Looking forward to seeing you there!

Warm regards,

The STAT Events Team

Email 4:

Subject: ‘A major advance, on the scale of an AlphaFold4’: the AI drug-discovery engine impressing scientists

Hello Nature readers,

Exciting developments in AI for drug discovery are underway with Isomorphic Labs’ new AI tool, IsoDDE, which excels at predicting protein-drug interactions—surpassing prior AI and physics-based approaches. This proprietary engine is promising a major leap akin to the impact of AlphaFold4 in structural biology.

Also in science this week:

– Conservation success as giant tortoises return to Floreana Island in Galápagos after 180 years.

– The enduring mystery of curling stone physics.

– An AI coach designed to make peer review comments more constructive and civil.

Explore deeper insights into artificial biology, librarian roles in research, and strategies to manage performance pressure in our featured articles.

Stay curious,

Flora Graham, Senior Editor, Nature Briefing

Stay Well!